Debt-to-equity of Rein Therapeutics, Inc. from 31 Mar 2018 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Rein Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2018 to 30 Sep 2025.
  • Rein Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 16%, a 92% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Rein Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 16% +7.9% +92% 30 Sep 2025
Q2 2025 14% +5.3% +62% 30 Jun 2025
Q1 2025 11% +2.3% +27% 31 Mar 2025
Q4 2024 9.7% -0.17% -1.7% 31 Dec 2024
Q3 2024 8.5% -7.4% -47% 30 Sep 2024
Q2 2024 8.5% -9.1% -52% 30 Jun 2024
Q1 2024 8.6% -10% -55% 31 Mar 2024
Q4 2023 9.8% -6.4% -39% 31 Dec 2023
Q3 2023 16% +2% +14% 30 Sep 2023
Q2 2023 18% +5.9% +50% 30 Jun 2023
Q1 2023 19% +9.4% +98% 31 Mar 2023
Q4 2022 16% +8.2% +103% 31 Dec 2022
Q3 2022 14% +4.8% +53% 30 Sep 2022
Q2 2022 12% -3.5% -23% 30 Jun 2022
Q1 2022 9.6% -16% -63% 31 Mar 2022
Q4 2021 8% -59% -88% 31 Dec 2021
Q3 2021 9.2% -64% -87% 30 Sep 2021
Q2 2021 15% -49% -76% 30 Jun 2021
Q1 2021 26% -28% -52% 31 Mar 2021
Q4 2020 67% +16% +32% 31 Dec 2020
Q3 2020 73% +25% +50% 30 Sep 2020
Q2 2020 64% +16% +33% 30 Jun 2020
Q1 2020 54% +7.8% +17% 31 Mar 2020
Q4 2019 51% +19% +62% 31 Dec 2019
Q3 2019 49% +27% +128% 30 Sep 2019
Q2 2019 48% +34% +245% 30 Jun 2019
Q1 2019 46% -46% -50% 31 Mar 2019
Q4 2018 31% 31 Dec 2018
Q3 2018 21% 30 Sep 2018
Q2 2018 14% 30 Jun 2018
Q1 2018 92% 31 Mar 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.